In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
First of its kind, two-year, 200-patient NEXT-2 trial utilized Guardant360 testing for therapy selection, and studied clinical response rates across multiple cancer types, including lung, gastric, melanoma, and rare cancers